Nichole James, Ph.D., Assistant Professor of Obstetrics and Gynecology (Research) at Brown University and Women and Infants Hospital. In this video, she speaks about the abstract Prognostic immunologic signatures in epithelial ovarian cancer.
Epithelial Ovarian Cancer (EOC) is a lethal gynecologic cancer that usually recurs after initial platinum-taxane chemotherapy. EOC clinical studies, like those for many other cancer subtypes, have focused on immunotherapeutic methods, most notably programmed cell death 1 (PD-1) inhibitors. While response rates to these immunotherapies have been modest in EOC patients, data suggests that ovarian cancers are immunogenic and that immune-related genetic profiles can serve as prognostic indicators. This review will describe recent achievements in the establishment of immune-based prognostic markers in EOC that predict patient clinical outcomes, as well as particular research topics that need to be addressed to further this field.